Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI ...

Eli Lilly, the pharmaceutical giant behind some of the most successful drugs in recent years, has announced plans to invest ...

On Friday, Aquestive Therapeutics, Inc. (NASDAQ:AQST) hosted a virtual investor day highlighting the company’s Anaphylm ...

Most patients with alopecia areata who had hair regrowth with baricitinib and discontinued maintenance therapy experienced a relapse of hair loss.

The observed lower mortality with remdesivir plus dexamethasone in patients on IMV/ECMO "further supports the growing ...

Incyte Corp's new patent details innovative methods for synthesizing baricitinib, a key rheumatoid arthritis treatment, enhancing pharmaceutical manufacturing processes.

Italy: A recent 24-week study conducted in Italy has yielded promising results regarding the effectiveness and safety of baricitinib for patients with severe alopecia areata (AA). The research, which ...

Reports of blood and lymphatic disorders were higher in pediatric patients treated with Janus kinase (JAK) inhibitors than in adults in a review of US and Canadian adverse event (AE) data, which ...

Indianapolis: Eli Lilly and Company and EVA Pharma have announced that the companies have entered into an agreement to expand access to baricitinib to an estimated 20,000 people in 49 low- to ...

Avenzo Therapeutics announced a clinical study collaboration with Gilead Sciences to evaluate AVZO-021 and Trodelvy in HR+/HER2- metastatic breast cancer. Eli Lilly and Company partnered with Haya ...

The new research, however, suggests that existing drugs such as baricitinib and anakinra can disrupt the malfunctioning immune response and finally allow damaged lungs to heal. "Our collaboration ...

Credit: rafa press/Shutterstock. Eli Lilly and EVA Pharma have formed a partnership to increase the availability of baricitinib in 49 low to middle-income African countries by 2030. Baricitinib is a ...